MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a non-invasive method to detect alcohol and drug intoxication using AI-driven voice analysis, a technology the company believes could serve as a scalable alternative to traditional biological sample testing. CEO Justin Hanka discussed the company’s plans in a recent TechMediaWire Podcast, highlighting that MindBio has built prediction models using over 50 million data points collected through years of clinical research. These models identify intoxication indicators associated with alcohol and drug use by analyzing speech patterns.
The technology is designed for deployment in safety-sensitive industries such as mining, aviation, construction, and law enforcement, where quick and reliable impairment detection is critical. MindBio is developing enterprise systems that combine proprietary software with Edge-AI kiosks capable of delivering assessments in less than three seconds. The company expects to begin live workplace testing during the second quarter of 2026, marking a step toward commercial adoption.
Traditional methods for detecting intoxication, such as breathalyzers or blood and urine tests, require biological samples and can be time-consuming or invasive. MindBio’s voice analysis approach could offer a faster, non-invasive alternative that can be administered remotely or at scale. The AI models have been trained on extensive data to recognize patterns associated with alcohol and various drugs, potentially providing a more comprehensive screening tool than tests targeting specific substances.
Beyond workplace impairment detection, management sees broader opportunities for AI-driven voice analytics as a diagnostic tool for identifying physiological and neurological conditions. The company’s technology could eventually be applied to detect conditions such as stress, fatigue, or even early signs of neurological disorders, expanding its potential market beyond safety compliance.
MindBio is a biotechnology company focused on commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company’s prediction model uses over 50 million data points to predict alcohol intoxication with high accuracy. The enterprise platform includes Edge-AI kiosks integrating bespoke hardware and software for detection in various industrial environments. For more information, visit the company’s newsroom at https://ibn.fm/MBQIF.
The development comes amid growing interest in non-invasive health monitoring technologies, particularly in industries where impairment poses significant risks. If successful, MindBio’s voice analysis system could provide employers with a tool to enhance workplace safety without the logistical challenges of biological sample collection. However, the technology still requires validation in real-world conditions, with live testing slated for 2026.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is MindBio Therapeutics Uses AI Voice Analysis to Detect Intoxication, Aiming for Workplace Safety Applications.